MedTrace Logo

Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study

NCT01213810 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-03-01

No results posted yet for this study

Summary

The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive individuals. Study participants are stratified into different patient groups according to their CD4 cell count, viral load and HIV Status.

* Trial with medicinal product
* Trial with immunomodulatory product / biological

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

Zostavax

Biological/Vaccine

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Barbara Hasse, MD · University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-12-31
Completion
2012-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213810 on ClinicalTrials.gov